Sivamurthy Nayan, Rhodes Jeffrey M, Lee David, Waldman David L, Green Richard M, Davies Mark G
Center for Vascular Disease, Department of Surgery, Division of Vascular Surgery, University of Rochester, Rochester, NY, USA.
J Am Coll Surg. 2006 Jun;202(6):859-67. doi: 10.1016/j.jamcollsurg.2006.02.019. Epub 2006 Apr 21.
Percutaneous therapy for symptomatic visceral occlusive disease is rapidly gaining popularity in many centers. This study evaluates the anatomic and functional outcomes of open and endovascular therapy for chronic mesenteric ischemia at an academic medical center.
We performed a retrospective review of patients who underwent endovascular or open mesenteric arterial revascularization for chronic mesenteric ischemia between January 1989 and September 2003. Indications for revascularization included postprandial abdominal pain (92%) or weight loss (54%). All had atherosclerotic visceral occlusive disease with a median of 2 vessels with more than 50% stenosis or occlusion on angiography. Sixty patients (44 women, mean age 66 years) underwent 67 interventions (43 vessels bypassed, 23 vessel endarterectomies, 22 vessel angioplasty and stents). The median numbers of vessels revascularized were two in the open group and one in the endovascular group.
Thirty-day mortality and cumulative survival at 3 years were similar (open, 15% and 62% +/- 9%; endovascular, 21% and 63%+/-14%, respectively; p=NS). Cumulative patencies at 6 months were 83%+/-7% and 68%+/-14% in the open and endovascular groups, respectively (p=NS). Major morbidity, median postoperative length of stay, and cumulative freedom from recurrent symptoms at 6 months were significantly greater in the open group (open, 46%, 23 days, and 71%+/-7%, respectively; endovascular, 19%, 1 day, and 34%+/-10%, respectively; p < 0.01).
Endovascular revascularization is attractive because it carries equivalent patency to open revascularization. Symptomatic benefit of endovascular revascularization is not achieved, probably as a result of incomplete revascularization. Despite incomplete revascularization, endovascular therapy has equivalent survival and lower morbidity compared with open revascularization. Complete endovascular revascularization needs further evaluation to determine if it is superior to open revascularization. In the interim, endovascular therapy should be reserved for the patient unable to undergo open revascularization.
经皮治疗有症状的内脏闭塞性疾病在许多中心正迅速普及。本研究评估了一所学术性医学中心对慢性肠系膜缺血进行开放手术和血管内治疗的解剖学及功能学结果。
我们对1989年1月至2003年9月间因慢性肠系膜缺血接受血管内或开放肠系膜动脉血运重建的患者进行了回顾性研究。血运重建的指征包括餐后腹痛(92%)或体重减轻(54%)。所有患者均患有动脉粥样硬化性内脏闭塞性疾病,血管造影显示中位数为2支血管有超过50%的狭窄或闭塞。60例患者(44例女性,平均年龄66岁)接受了67次干预(43支血管旁路移植术、23支血管内膜切除术、22支血管血管成形术和支架置入术)。开放手术组血运重建的血管中位数为2支,血管内治疗组为1支。
30天死亡率和3年累积生存率相似(开放手术组分别为15%和62%±9%;血管内治疗组分别为21%和%63±14%;p=无显著性差异)。开放手术组和血管内治疗组6个月时的累积通畅率分别为83%±7%和68%±14%(p=无显著性差异)。开放手术组的主要并发症、术后中位住院时间和6个月时累积无复发症状率显著更高(开放手术组分别为46%、23天和71%±7%;血管内治疗组分别为19%、1天和34%±10%;p<(0.01)。
血管内血运重建具有吸引力,因为其通畅率与开放血运重建相当。血管内血运重建未实现症状改善,可能是由于血运重建不完全。尽管血运重建不完全,但与开放血运重建相比,血管内治疗具有相同的生存率且并发症更低。完全血管内血运重建需要进一步评估,以确定其是否优于开放血运重建。在此期间,血管内治疗应仅用于无法接受开放血运重建的患者。